Exact Mass: 438.244
Exact Mass Matches: 438.244
Found 500 metabolites which its exact mass value is equals to given mass value 438.244
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Quinapril
Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
acetyl-(2-furyl)-trimethyl-[?]one
Licorisoflavan A
Licorisoflavan A is found in herbs and spices. Licorisoflavan A is a constituent of Glycyrrhiza uralensis (Chinese licorice). Constituent of Glycyrrhiza uralensis (Chinese licorice). Licorisoflavan A is found in herbs and spices.
LysoPA(0:0/18:0)
LysoPA(0:0/18:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
LysoPA(18:0/0:0)
LysoPA(18:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
1,4-Bis((p-propylphenoxy)acetyl)piperazine
7,7-Diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one
N-[4-[2-(6-Cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]quinoline-4-carboxamide
ent-13S-Hydroxy-14R,15-diacetoxy-1(10)-halimen-18-oic acid
3-[4,8-Bis[(acetyloxy)methyl]-13-hydroxy-12-methyl-11-tridecenyl]-2(5H)-furanone
ent-13R-Hydroxy-14S,15-diacetoxy-1(10)-halimen-18-oic acid
8, 18-Di-Ac-(4beta, 8alpha, 9alpha, 14beta)-3(16)-Fusicoccene-4, 8, 9, 14, 18-pentol|Fusicoplagin A
8-hydroxy-5-methyl-7-(3,7-dimethylocta-2,6-dienyl)-9-(3-methyl-1-oxobutyl)-4,5-dihydropyrano[4,3,2-de]chromen-2-one
16(R)-1alpha,3beta,7beta-trihydroxy-17-methoxy-11beta-acetoxy-ent-kaur-6,15-dione|tenuifolin L
(3alpha,7beta,9alpha,8alpha,15alpha)-3-(acetyloxy)-9,13:15,16-diepoxy-15-ethoxy-7-hydroxylabdan-6-one|rel-(1R,2S,2R,3R,4aS,5S,6R,8aS)-6-(acetyloxy)-5-ethoxydodecahydro-3-hydroxy-2,5,5,8a;-tetramethyldispiro[furan-3(2H),2(5H)-furan-5,1(4H)-naphthalen]-4-one
2-(2,5,5,8a-Tetramethyl-3-oxo-3,5,6,7,8,8a-hexahydronaphthalene-1-yl)-4-acetoxymethyl-7-methyl-4a,8a-dihydro-2H-1-benzopyran-6(5H)-one
8-hydroxy-5-methyl-7-(3,7-dimethylocta-2,6-dienyl)-9-(2-methyl-1-oxobutyl)-4,5-dihydropyrano[4,3,2-de]chromen-2-one
15beta-O-benzoyl-5alpha-hydroxyisolathyrol
A lathyrane diterpenoid isolated from the roots of Euphorbia micractina.
cyclo{L-alanyl-D-alanyl-[(2S,9S)-2-amino-9-hydroxy-8-oxodecanoyl]-D-prolyl}|JM47
JW8U2YD8JL
Licorisoflavan A is a member of the class of hydroxyisoflavans that is the 7-O-methyl derivative of licoricidin. Isolated from Glycyrrhiza uralensis, it exhibits antibacterial activity. It has a role as an antibacterial agent and a plant metabolite. It is an aromatic ether, a member of hydroxyisoflavans and a methoxyisoflavan. It is functionally related to a licoricidin. 5-O-Methyllicoricidin is a natural product found in Glycyrrhiza uralensis and Glycyrrhiza aspera with data available. See also: Glycyrrhiza uralensis Root (part of). A member of the class of hydroxyisoflavans that is the 7-O-methyl derivative of licoricidin. Isolated from Glycyrrhiza uralensis, it exhibits antibacterial activity.
Ala Phe Thr Thr
Ala His Ile Val
Ala His Leu Val
Ala His Val Ile
Ala His Val Leu
Ala Ile His Val
Ala Ile Val His
Ala Leu His Val
Ala Leu Val His
Ala Ser Val Tyr
Ala Val His Ile
Ala Val His Leu
Ala Val Ile His
Ala Val Leu His
Phe Thr Thr Ala
Phe Val Ser Ser
Gly His Ile Ile
Gly His Ile Leu
Gly His Leu Ile
Gly His Leu Leu
Gly Ile His Ile
Gly Ile His Leu
Gly Ile Ile His
Gly Ile Leu His
Gly Ile Ser Tyr
Gly Ile Tyr Ser
Gly Leu His Ile
Gly Leu His Leu
Gly Leu Ile His
Gly Leu Leu His
Gly Leu Ser Tyr
Gly Leu Tyr Ser
Gly Ser Ile Tyr
Gly Ser Leu Tyr
Gly Ser Tyr Ile
Gly Ser Tyr Leu
Gly Thr Val Tyr
Gly Thr Tyr Val
Gly Val Thr Tyr
Gly Val Tyr Thr
Gly Tyr Ile Ser
Gly Tyr Leu Ser
Gly Tyr Ser Ile
Gly Tyr Ser Leu
Gly Tyr Thr Val
Gly Tyr Val Thr
His Ala Ile Val
His Ala Leu Val
His Ala Val Ile
His Ala Val Leu
His Gly Ile Ile
His Gly Ile Leu
His Gly Leu Ile
His Gly Leu Leu
His Ile Ala Val
His Ile Gly Ile
His Ile Gly Leu
His Ile Ile Gly
His Ile Leu Gly
His Ile Val Ala
His Leu Ala Val
His Leu Gly Ile
His Leu Gly Leu
His Leu Ile Gly
His Leu Leu Gly
His Leu Val Ala
His Pro Ser Val
His Pro Val Ser
His Ser Pro Val
His Ser Val Pro
His Val Ala Ile
His Val Ala Leu
His Val Ile Ala
His Val Leu Ala
His Val Pro Ser
His Val Ser Pro
Ile Ala His Val
Ile Ala Val His
Ile Gly His Ile
Ile Gly His Leu
Ile Gly Ile His
Ile Gly Leu His
Ile Gly Ser Tyr
Ile Gly Tyr Ser
Ile His Ala Val
Ile His Gly Ile
Ile His Gly Leu
Ile His Ile Gly
Ile His Leu Gly
Ile His Val Ala
Ile Ile Gly His
Ile Ile His Gly
Ile Leu Gly His
Ile Leu His Gly
Ile Ser Gly Tyr
Ile Ser Tyr Gly
Ile Val Ala His
Ile Val His Ala
Ouabagenin
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D013328 - Strophanthins
Ile Tyr Gly Ser
Ile Tyr Ser Gly
Leu Ala His Val
Leu Ala Val His
Leu Gly His Ile
Leu Gly His Leu
Leu Gly Ile His
Leu Gly Leu His
Leu Gly Ser Tyr
Leu Gly Tyr Ser
Leu His Ala Val
Leu His Gly Ile
Leu His Gly Leu
Leu His Ile Gly
Leu His Leu Gly
Leu His Val Ala
Leu Ile Gly His
Leu Ile His Gly
Leu Leu Gly His
Leu Leu His Gly
Leu Ser Gly Tyr
Leu Ser Tyr Gly
Leu Val Ala His
Leu Val His Ala
Leu Tyr Gly Ser
Leu Tyr Ser Gly
Pro His Ser Val
Pro His Val Ser
Pro Ser His Val
Pro Ser Val His
Pro Val His Ser
Pro Val Ser His
Ser His Pro Val
Ser His Val Pro
Ser Pro His Val
Ser Pro Val His
Ser Val His Pro
Ser Val Pro His
Val Ala His Ile
Val Ala His Leu
Val Ala Ile His
Val Ala Leu His
Val His Ala Ile
Val His Ala Leu
Val His Ile Ala
Val His Leu Ala
Val His Pro Ser
Val His Ser Pro
Val Ile Ala His
Val Ile His Ala
Val Leu Ala His
Val Leu His Ala
Val Pro His Ser
Val Pro Ser His
Val Ser His Pro
Val Ser Pro His
Val Tyr Ala Ser
3-[2-Methyl-4-(diethylamino)phenyl]-3-(1,2-dimethyl-3-indolyl)phthalide
TERT-BUTYL 4-((TERT-BUTYLDIPHENYLSILYL)OXY)CYCLOHEXANECARBOXYLATE
Methyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarbox ylate
1,3-diisocyanato-2-methylbenzene,2-ethylhexan-1-ol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol
1-Palmityl-2-acetyl-sn-glycero-3-phosphate
A 1-alkyl-2-acyl-sn-glycerol 3-phosphate in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and acetyl respectively.
[(2R)-3-hydroxy-2-(octadecanoyloxy)propoxy]phosphonic acid
leukotriene E4(1-)
The leukotriene anion that is the conjugate base of leukotriene E4 arising from deprotonation of the two carboxy groups and protonation of the cysteinyl alpha-amino group.
N(1),N(8)-bis(coumaroyl)spermidine(1+)
An ammonium ion resulting from the protonation of the non-acylated nitrogen of N(1),N(8)-bis(coumaroyl)-spermidine. The major species at pH 7.3.
2-p-Chlorophenyl-1-(p-(2-diethylaminoethoxy)phenyl)-1-p-tolylethanol
(3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-6-hydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
Tritoniopsin B, rel-
A natural product found in Tritoniopsis elegans and Cladiella krempfi.
(+)-(12E,2S,3S,4R,5R,6R,9S,11S,15R)-3-benzoyloxy-5,6-epoxylathyr-12-en-15-ol-14-one
A lathyrane diterpenoid isolated from the roots of Euphorbia micractina.
2-(2-methoxyethyl)-9-methyl-N-[3-(4-methyl-1-piperidinyl)propyl]-1-oxo-4-pyrido[3,4-b]indolecarboxamide
Ethyl 4-[9-methyl-2-(2-methylpropyl)-1-oxopyrido[3,4-b]indole-4-carbonyl]piperazine-1-carboxylate
7-[3-[4-(2-Ethoxyphenyl)-1-piperazinyl]-2-hydroxypropoxy]-4-methyl-1-benzopyran-2-one
[(1S,2S,5R,6R,8R,9S,10S,11R,15S,18R)-9,10,18-trihydroxy-6-(methoxymethyl)-12,12-dimethyl-7-oxo-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-15-yl] acetate
[1-[(3,5-Dimethyl-4-isoxazolyl)sulfonyl]-4-piperidinyl]-[4-(1-piperidinyl)-1-piperidinyl]methanone
16alpha,17-Dihydroxypregn-4-ene-3,20-dione cyclic acetal with 2-furyl methyl ketone
N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
(1R)-N-cyclopentyl-2-(cyclopropylmethyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[(4-methylphenyl)sulfonylamino]-2-oxanyl]ethyl]cyclohexanecarboxamide
(1S)-N-cyclopentyl-2-(cyclopropylmethyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
1-[(2S,3R)-3-[4-(2-fluorophenyl)phenyl]-2-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
1-(3-Methoxypropyl)-4-[2-methyl-4-(2-methylpropoxy)benzoyl]-5-pyridin-3-ylpyrrolidine-2,3-dione
2-[[(2R)-2-acetyloxy-3-dec-9-enoxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-17-(5-hydroxyfuran-3-yl)-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1,3,5,11,14-pentol
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) nonanoate
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) tridecanoate
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) dodecanoate
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) decanoate
(1-Acetyloxy-3-phosphonooxypropan-2-yl) pentadecanoate
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) undecanoate
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) tetradecanoate
(E.E)-(1R,2S,5R)-8-beta-Naphthylmenthyl-5-phenyl-2,4-pentadienoate
Quinapril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
1-Stearoyl-sn-glycero-3-phosphate
A 1-acyl-sn-glycerol 3-phosphate in which the 1-acyl substituent is specified as stearoyl (octadecanoyl).
5,7-diethyl-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-1,6-naphthyridin-2-one
D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers
lysophosphatidic acid 18:0
A lysophosphatidic acid in which the acyl group (position not specified) contains 18 carbons and no double bonds.
LPEt(16:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(2r,3r)-3-[2-(2,2-dimethyl-6-methylidenecyclohexyl)ethyl]-2-ethyl-4-hydroxy-7-methoxy-3-methyl-2h-naphtho[1,2-b]furan-6,9-dione
ethyl 2-[2-(acetyloxy)-12-hydroxy-1,5,12-trimethyl-6,16-dioxatricyclo[11.2.1.0⁵,⁷]hexadecan-9-yl]prop-2-enoate
(6e)-7-[6-(hydroxymethyl)-6-methyl-5-oxo-dihydro-3h-spiro[furo[3,2-b]furan-2,2'-oxolan]-5'-yl]hepta-4,6-dien-2-yl 3-hydroxy-2-methylbutanoate
(1s,2s,3s,5s,6s,8s,9s,10s,11r,15s)-3,9,10-trihydroxy-6-(methoxymethyl)-12,12-dimethyl-7-oxo-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-15-yl acetate
(1s,2s,5s,6s,8r,9s,10s,11r,15s,18r)-9,10,18-trihydroxy-6-(methoxymethyl)-12,12-dimethyl-7-oxo-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-15-yl acetate
1-[1,2-bis(acetyloxy)-5-oxocyclopent-3-en-1-yl]tridecyl acetate
4'-hydroxy-2',4'b,6,7,8',8',10'a-heptamethyl-4'a,8'a,9',10'-tetrahydro-3h,4'h-spiro[furo[3,2-c]pyran-2,1'-phenanthrene]-4,7'-dione
(1s,5s,6r,8as)-5-[(3r,4s)-4,5-bis(acetyloxy)-3-hydroxy-3-methylpentyl]-1,5,6-trimethyl-2,3,6,7,8,8a-hexahydronaphthalene-1-carboxylic acid
(1s,2s,6s,7r,8r,10s,13r)-8-(benzoyloxy)-2,6,13-trimethyl-12-oxotetracyclo[11.2.1.0¹,¹⁰.0²,⁷]hexadecane-6-carboxylic acid
n-(4-{[1-hydroxy-3-(3-methoxy-4-methylphenyl)prop-2-en-1-ylidene]amino}butyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enimidic acid
[3,9,10-trihydroxy-6-(methoxymethyl)-12-methyl-7-oxo-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-12-yl]methyl acetate
4-oxo-4-{[(2r,3r,4e,6s,8e,10e,12e,15r,16s)-6,15,16-trihydroxy-3,5-dimethyloctadeca-4,8,10,12-tetraen-2-yl]oxy}butanoic acid
4a,6-dihydroxy-4,4,7,11b-tetramethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-5-yl benzoate
(1r,2r,4r,7s,9r,10e,13r,15s,16s)-16-hydroxy-4,8,8,11,15-pentamethyl-12-oxo-3-oxatetracyclo[11.3.0.0²,⁴.0⁷,⁹]hexadec-10-en-13-yl benzoate
(1r,2s,3s,5s,6s,8s,9s,10s,11r,15s)-9,10,15-trihydroxy-6-(methoxymethyl)-12,12-dimethyl-7-oxo-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-3-yl acetate
1-[6-(acetyloxy)-3-hydroxy-7-methyl-4-methylidene-octahydro-1h-naphtho[4,4a-c]furan-7-yl]-4-hydroxy-4-methylpentan-3-yl acetate
(2r,9s,13s,15r,17r,25r)-17-ethyl-21,22-dimethoxy-12,19-dioxa-5,16-diazaheptacyclo[14.7.1.1²,⁵.0²,¹⁵.0⁹,¹³.0²⁰,²⁴.0⁹,²⁵]pentacosa-1(24),7,20,22-tetraen-11-one
(2s)-2-[4-hydroxy-2-({[(2s)-2-[4-hydroxy-2-(hydroxymethyl)but-1-en-1-yl]-5-methylhex-4-enoyl]oxy}methyl)but-1-en-1-yl]-5-methylhex-4-enoic acid
(5ar,7ar,9s,11as,11br)-9-hydroxy-3-(4-methoxyphenyl)-5a,8,8,11a-tetramethyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-1-one
4a,7-dihydroxy-4,4,7,11b-tetramethyl-1h,2h,3h,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-5-yl benzoate
6-{[2-(4a-methyl-8-methylidene-octahydronaphthalen-2-yl)propan-2-yl]oxy}-4-(acetyloxy)-5-hydroxyoxan-3-yl acetate
(1r,2r,3s,5s,7r,8r,10s,11s,14r)-14-(acetyloxy)-5,10-dihydroxy-3-isopropyl-10,14-dimethyl-6-methylidene-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-11-yl acetate
(2s,4's,4'ar,4'bs,8'ar,10'ar)-4'-hydroxy-2',4'b,6,7,8',8',10'a-heptamethyl-4'a,8'a,9',10'-tetrahydro-3h,4'h-spiro[furo[3,2-c]pyran-2,1'-phenanthrene]-4,7'-dione
4-episcopadulcicacid b
{"Ingredient_id": "HBIN010368","Ingredient_name": "4-episcopadulcicacid b","Alias": "NA","Ingredient_formula": "C27H34O5","Ingredient_Smile": "CC12CCC3(C1)C(CC(C4C3(CCCC4(C)C(=O)O)C)OC(=O)C5=CC=CC=C5)CC2=O","Ingredient_weight": "438.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7015","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10917156","DrugBank_id": "NA"}
6β-benzoyl-7β-hydroxyvouacapen-5α-ol
{"Ingredient_id": "HBIN012260","Ingredient_name": "6\u03b2-benzoyl-7\u03b2-hydroxyvouacapen-5\u03b1-ol","Alias": "NA","Ingredient_formula": "C27H34O5","Ingredient_Smile": "CC1C2C(CC3=C1C=CO3)C4(CCCC(C4(C(C2O)OC(=O)C5=CC=CC=C5)O)(C)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2244","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}